BC Extra | Nov 27, 2014
Financial News

S1 Biopharma amends IPO

S1 Biopharma Inc. (New York, N.Y.) amended its IPO on NASDAQ and plans to sell 1.75 million units at $12-$14. At $13, the company would raise $22.8 million and be valued at $105.7 million. Each...
BC Extra | Oct 24, 2014
Financial News

S1 Biopharma sets IPO range

S1 Biopharma Inc. (New York, N.Y.) amended its IPO on NASDAQ and plans to sell 2.8 million shares at $12-$14. At $13, the company would raise $35.8 million and be valued at $118.6 million. S1...
BC Extra | Oct 2, 2014
Financial News

S1 Biopharma files for IPO

S1 Biopharma Inc. (New York, N.Y.) proposed to raise up to $40.3 million in an IPO on NASDAQ underwritten by MLV. The biotech's lead product is lorexys , an oral fixed-dose enteric formulation of bupropion and...
BioCentury | Dec 16, 2013
Strategy

Out in the cold

New excluded drugs lists devised by pharmacy benefits managers are raising the hurdle for reimbursement of drugs the PBMs' pharmacy and therapeutics committees consider to be clinically equivalent to cheaper drugs. Drugs that are not...
BC Week In Review | Aug 5, 2013
Clinical News

Lorexys: Phase IIa started

S1 Biopharma began the open-label, 3-way crossover, U.S. Phase IIa PURPLE trial to compare daily Lorexys vs. daily bupropion in 30 premenopausal women with HSDD. Patients will sequentially receive bupropion, low-dose Lorexys and a moderate...
BC Week In Review | Aug 29, 2011
Company News

Labopharm, Angelini deal

In July, companies said they would terminate their JV, Angelini Labopharm LLC, and Labopharm would transfer its 50% stake in the JV to Angelini. The JV was formed in May 2010 to market major depressive...
BC Week In Review | Aug 22, 2011
Company News

Labopharm, Paladin deal

Paladin will acquire Labopharm for C$0.29 per share in cash, or C$20.4 million ($20.7 million) based on 71.6 million shares outstanding at Aug. 2. The price is a 68% premium to Labopharm's close of C$0.17...
BC Week In Review | Jul 4, 2011
Company News

Labopharm, Angelini neurology, drug delivery news

Labopharm said its JV with Angelini, Angelini Labopharm, reduced its U.S. sales force for major depressive disorder (MDD) drug Oleptro trazodone by 65 (50%) to 65 to reduce costs. The reduction is expected to save...
BC Week In Review | May 9, 2011
Company News

Labopharm, Angelini deal

Labopharm said it has entered into discussions with Gruppo Angelini to restructure their deal covering major depressive disorder (MDD) drug Oleptro trazodone in the U.S. to further preserve capital as part of Labopharm's ongoing review...
BC Week In Review | Mar 28, 2011
Company News

Labopharm neurology, drug delivery news

Labopharm also named VP and Corporate Controller Sylvain Guenette to CFO. Labopharm Inc. (TSX:DDS; NASDAQ:DDSS), Laval, Quebec   Business: Neurology, Drug delivery   Labopharm reduced headcount by 38 (29%) to 94 to save cash while...
Items per page:
1 - 10 of 52